AstraZeneca – Scientific Innovation in Modern Medicine

AstraZeneca

Country: United Kingdom

AstraZeneca PLC is a British-Swedish biopharmaceutical company formed in 1999 through the merger of Sweden's Astra AB and Britain's Zeneca Group. It is headquartered in Cambridge, UK. Its primary listing is on the London Stock Exchange, where it is part of the FTSE 100, and its shares also trade on Nasdaq Stockholm and the New York Stock Exchange.

AstraZeneca's main areas are oncology, cardiovascular, renal and metabolic diseases, respiratory medicine and immunology, plus rare diseases through Alexion, acquired in 2021. Its well-known medicines include Forxiga (dapagliflozin), Imfinzi (durvalumab) and Enhertu (trastuzumab deruxtecan), developed with Daiichi Sankyo.

During the COVID-19 pandemic, AstraZeneca and the University of Oxford developed a coronavirus vaccine, which the UK authorised for emergency use in December 2020.

In oncology the company is known for targeted therapies. Olaparib (Lynparza) became the first approved PARP inhibitor in 2014, for BRCA-mutated ovarian cancer; it is now co-marketed by AstraZeneca and MSD. Osimertinib (Tagrisso) is a third-generation EGFR inhibitor for non-small cell lung cancer, approved by the FDA in 2015.

Unifarm carries AstraZeneca's oncology medicines: Tagrisso 80 (osimertinib) and Lynparza 150 (olaparib).

Official manufacturer website
AstraZeneca

List of medicines by manufacturer AstraZeneca

-7%
Tagrisso 80
View
AstraZeneca
80 mg 30 tablets
116220₴ 125115₴
-1%
Lynparza 150
View
AstraZeneca
150 mg
96540₴ 97450₴
✅ All products loaded (2)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00